Vorinostat in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma

What is the purpose of this trial?

The standard therapy of large cell lymphoma uses a combination of the drugs cyclophosphamide, doxorubicin, vincristine, and prednisone (called "CHOP") with the rituximab antibody. CHOP is a common chemotherapy for lymphoma. The rituximab antibody is a protein that targets specific cells that are related to large cell lymphoma. The combination of rituximab-CHOP chemotherapy has been used to treat patients with lymphoma and has been shown to be active against lymphoma. This experimental study is being done to test the best dose and safety for using vorinostat (SAHA) together with rituximab-CHOP. It is also being done to see if patients treated with the vorinostat rituximab-CHOP chemotherapy will have longer lasting tumor shrinkage than patients treated with CHOP chemotherapy and rituximab alone. This study will be conducted in two parts. Patients will take part in either Part I or Part II, not both. In the first part of the study, patients will be treated with a specific dose of vorinostat along with the rituximab-CHOP chemotherapy. If this vorinostat dose causes bad side effects, it will be decreased as new patients take part in the study. Once the maximum safe dose of vorinostat is decided, the first part of the study will end and the second part of the study will start. In the second part of the study, patients will be treated with the vorinostat dose (determined from Part I) and the CHOP-rituximab chemotherapy.

---

Participation Guidelines

Click here for detailed information about who can participate in this trial.

---

Sponsor:

Southwestern Oncology Group (SWOG)

Dates:

August 2012

Last Updated:

Study HIC#:

1207010544

Clinicaltrials.gov ID: Yale6605449